Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs

Journal of Pharmacological and Toxicological Methods

Volumn 56, Issue 2, 2007, Pages 131-144

  Ollerstam, Anna ^a   Visser, Sandra A G ^a   Duker, Göran ^b   Forsberg, Tomas ^a   Persson, Anna H ^a   Nilsson, Lars B ^a   Björkman, Jan Arne ^b   Gabrielsson, Johan ^b   Al Saffar, Ahmad ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Cisapride; Dofetilide; Dog; ECG; Methods; Moxifloxacin; Pharmacokinetic pharmacodynamic; QT interval; Terfenadine; Unbound concentrations

Indexed keywords

CISAPRIDE; DOFETILIDE; MOXIFLOXACIN; TERFENADINE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CARDIOTOXICITY; COMPARATIVE STUDY; CONSCIOUS SEDATION; CONTROLLED STUDY; DOG; DRUG MEGADOSE; FEMALE; HEART ATRIUM PACING; LOW DRUG DOSE; MALE; NONHUMAN; QT INTERVAL; QT PROLONGATION; SENSITIVITY ANALYSIS; SIGNAL DETECTION; SINUS RHYTHM; TELEMETRY;

ANESTHESIA; ANIMALS; AZA COMPOUNDS; CARDIAC PACING, ARTIFICIAL; CISAPRIDE; CONSCIOUSNESS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HALF-LIFE; HEART RATE; INFUSIONS, INTRAVENOUS; LONG QT SYNDROME; MALE; MODELS, ANIMAL; PHENETHYLAMINES; QUINOLINES; SINOATRIAL NODE; SULFONAMIDES; TELEMETRY; TERFENADINE; TIME FACTORS;

CANIS FAMILIARIS;

EID: 34548523702     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2007.05.002     Document Type: Article

References (49)

1. Brown A.M. Drugs, hERG and sudden death. Cell Calcium 35 (2004) 543-547
2. Camm A.J. Clinical trial design to evaluate the effects of drugs on cardiac repolarization: Current state of the art. Heart Rhythm 2 (2005) S23-S29
3. Carlsson L., Abrahamsson C., Andersson B., Duker G., and Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovascular Research 27 (1993) 2186-2193
4. Chiba K., Sugiyama A., Hagiwara T., Takahashi S., Takasuna K., and Hashimoto K. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. European Journal of Pharmacology 486 (2004) 189-200
5. Davidowski T.A., and Wolf S. The QT interval during reflex cardiovascular adaptation. Circulation 69 (1984) 22-25
6. Detre E., Thomsen M.B., Beekman D., Petersen K.U., and Vos M.A. Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: Confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes. British Journal of Pharmacology 145 (2005) 397-404
7. Gladziwa U., Bares R., Klotz U., Dakshinamurty K.V., Ittel T.H., Seiler K.U., et al. Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. Clinical Pharmacology & Therapeutics 50 (1991) 673-681
8. Gralinski M.R. The assessment of potential for QT interval prolongation with new pharmaceuticals: Impact on drug development. Journal of Pharmacological & Toxicological Methods 43 (2000) 91-99
9. Hammond T.G., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Redfern W.S., et al. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey. Cardiovascular Research 49 (2001) 741-750
10. Harada T., Abe J., Shiotani M., Hamada Y., and Horii I. Effect of autonomic nervous function on QT interval in dogs. Journal of Toxicological Sciences 30 (2005) 229-237
11. Hondeghem L.M., and Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 81 (1990) 686-690
12. ICH harmonised tripartite guideline, S7A. Safety pharmacology studies for human pharmaceuticals (2000)
13. ICH harmonised tripartite guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B) (2005)
14. Johansson L., Sohn D., Thorberg S.-O., Jackson D.M., Kelder D., Larsson L.-G., et al. The pharmacological characterization of a novel selective 5-hydroxytryptamine1a receptor antagonist, NAD-299. Journal of Pharmacology and Experimental Therapeutics 283 (1997) 216-225
15. + channel HERG. Molecular Pharmacology 59 (2001) 122-126
16. Kleinbloesem C.H., Van Brummelen P., Danhof M., Faber H., Urquhart J., and Breimer D.D. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clinical Pharmacology & Therapeutics 41 (1987) 26-30
17. Klumpp A., Trautmann T., Markert M., and Guth B. Optimizing the experimental environment for dog telemetry studies. Journal of Pharmacological & Toxicological Methods 54 (2006) 141-149
18. Lacroix P., Crumb W.J., Durando L., and Ciottoli G.B. Prulifloxacin: In vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. European Journal of Pharmacology 477 (2003) 69-72
19. Lawrence C., Abi-Gereges N., Small B., Jansson S., Harmen B., Ohman P., et al. A comparison of clinical and non-clinical data for moxifloxacin. Journal of Pharmacological and Toxicological Methods 54 (2006) 246
20. Le Coz F., Funck-Brentano C., Morell T., Ghadanfar M.M., and Jaillon P. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clinical Pharmacology & Therapeutics 57 (1995) 533-542
21. Leeson G.A., Chan K.Y., Knapp W.C., Biedenbach S.A., Wright G.J., and Okerholm R.A. Metabolic disposition of terfenadine in laboratory animals. Arzneimittel-Forschung 32 (1982) 1173-1178
22. Liu S., Melchert R.B., and Kennedy R.H. Inhibition of L-type Ca2+ channel current in rat ventricular myocytes by terfenadine. Circulation Research 81 (1997) 202-210
23. Lu Y., and Wang Z. Terfenadine block of sodium current in canine atrial myocytes. Journal of Cardiovascular Pharmacology 33 (1999) 507-513
24. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., and Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. Journal of Cardiovascular Pharmacology 43 (2004) 369-379
25. Meuldermans W., Van Peer A., Hendrickx J., Lauwers W., Swysen E., Bockx M., et al. Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metabolism and Disposition 16 (1988) 403-409
26. Michiels M., Monbaliu J., Hendriks R., Geerts R., Woestenborghs R., and Heykants J. Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog. Arzneimittel-Forschung 37 (1987) 1159-1167
27. Minematsu T., Ohtani H., Yamada Y., Sawada Y., Sato H., and Iga T. Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: Pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect. Journal of Pharmacokinetics & Pharmacodynamics 28 (2001) 533-554
28. Ming Z., and Nordin C. Terfenadine blocks time-dependent Ca2+, Na+, and K+ channels in guinea pig ventricular myocytes. Journal of Cardiovascular Pharmacology 26 (1995) 761-769
29. Noel G.J., Natarajan J., Chien S., Hunt T.L., Goodman D.B., and Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clinical Pharmacology & Therapeutics 73 (2003) 292-303
30. Nolan E.R., Feng M.R., Koup J.R., Liu J., Turluck D., Zhang Y., et al. A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic AV node-Ablated, His bundle-paced dog. Journal of Pharmacological & Toxicological Methods 53 (2006) 1-10
31. Obreztchikova M.N., Patberg K.W., Plotnikov A.N., Ozgen N., Shlapakova I.N., Rybin A.V., et al. IKr contributes to the altered ventricular repolarization that determines long-term cardiac memory. Cardiovascular Research 71 (2006) 88-96
32. Ollerstam A., Persson A.H., Visser S.A.G., Fredriksson J.M., Forsberg T., Nilsson L.B., et al. A novel approach to data processing of the QT interval response in the conscious telemetered beagle dog. Journal of Pharmacological and Toxicological Methods 55 (2007) 35-48
33. Ollerstam A., Visser S.A.G., Persson A.H., Eklund G., Nilsson L.B., Forsberg T., et al. Pharmacokinetic-pharmacodynamic modelling of drug-induced effect on the QT interval in conscious telemetered dogs. Journal of Pharmacological and Toxicological Methods 53 (2006) 174-183
34. Peters R.W., Byington R.P., Barker A., and Yusuf S. Prognostic value of prolonged ventricular repolarization following myocardial infarction: The BHAT experience. The BHAT Study Group. Journal of Clinical Epidemiology 43 (1990) 167-172
35. Picard S., and Lacroix P. QT interval prolongation and cardiac risk assessment for novel drugs. Current Opinion in Investigational Drugs 4 (2003) 303-308
36. Rampe D., Murawsky M.K., Grau J., and Lewis E.W. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. Journal of Pharmacology and Experimental Therapeutics 286 (1998) 788-793
37. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
38. Siefert H.M., Domdey-Bette A., Henninger K., Hucke F., Kohlsdorfer C., and Stass H.H. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: A comparison in humans and other mammalian species. Journal of Antimicrobial Chemotherapy 43 (1999) 69-76
39. Smith D.A., Rasmussen H.S., Stopher D.A., and Walker D.K. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 22 (1992) 709-719
40. Tashibu H., Miyazaki H., Aoki K., Akie Y., and Yamamoto K. QT PRODACT: In vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. Journal of Pharmacological Sciences 99 (2005) 473-486
41. Van Haarst A.D., Van't Klooster G.A.E., Van Gerven J.M.A., Schoemaker R.C., Van Oene J.C., Burggraaf J., et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clinical Pharmacology & Therapeutics 64 (1998) 542-546
42. Veereman-Wauters G., Monbaliu J., Meuldermans W., Woestenborghs R., Verlinden M., Heykants J., et al. Study of the placental transfer of cisapride in sheep. Plasma levels in the pregnant ewe, the fetus, and the lamb. Drug Metabolism and Disposition 19 (1991) 168-172
43. Volders P.G.A., Stengl M., van Opstal J.M., Gerlach U., Spatjens R.L.H.M.G., Beekman J.D.M., et al. Probing the contribution of IKs to canine ventricular repolarization: Key role for {beta}-adrenergic receptor stimulation. Circulation 107 (2003) 2753-2760
44. Walker D.K., Beaumont K.C., Stopher D.A., and Smith D.A. Pharmacokinetics of a series of bis(methanesulphonamido-arylalkyl)amines in the beagle dog. Xenobiotica 26 (1996) 1101-1111
45. Wang J., Della Penna K., Wang H., Karczewski J., Connolly T.M., Koblan K.S., et al. Functional and pharmacological properties of canine ERG potassium channels. American Journal of Physiology-Heart & Circulatory Physiology 284 (2003) H256-H267
46. Webster R., Allan G., Anto-Awuakye K., Harrison A., Kidd T., Leishman D., et al. Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. Xenobiotica 31 (2001) 633-650
47. Wolbrette D.L. Drugs that cause torsades de pointes and increase the risk of sudden cardiac death. Current Cardiology Reports 6 (2004) 379-384
48. Yamamoto K., Tamura T., Imai R., and Yamamoto M. Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. Toxicological Science 60 (2001) 165-176
49. Zehelein J., Zhang W., Koenen M., Graf M., Heinemann S.H., and Katus H.A. Molecular cloning and expression of cERG, the ether à go-go-related gene from canine myocardium. Pflugers Archiv 442 (2001) 188-191